Risk Factors for Prognosis of Lung Cancer Patients Receiving Anlotinib Treatment: A Retrospective Cohort Study
Clinical stage IV, NT-pro-BNP level, and NSE level were identified as independent prognostic factors for lung cancer patients undergoing anlotinib treatment. Patients with multiple high-risk factors may derive limited benefit from anlotinib.
Authors
- Jinzhan Chen (ORCID: https://orcid.org/0009-0001-6778-3623)
- Congyi Xie (ORCID: https://orcid.org/0009-0006-3860-571X)
- Shuwen Yang (ORCID: https://orcid.org/0009-0000-9724-8245)
- Lin Yang (ORCID: https://orcid.org/0000-0002-5183-2101)
- Tong Lin (ORCID: https://orcid.org/0000-0003-1181-3763)
- Yijiao Xu (ORCID: https://orcid.org/0000-0002-4685-2378)
- Yimin Yang (ORCID: https://orcid.org/0000-0003-4087-8515)
- Feiyang Ye
Institutions
- Fudan University (CN)
- Zhongshan Hospital of Xiamen University (CN)
- Zhongshan Hospital (CN)
- Fuzhou University (CN)
Publication Details
- Journal
- The Clinical Respiratory Journal
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1111/crj.70051
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Fudan University
- Natural Science Foundation of Fujian Province
- Science and Technology Commission of Shanghai Municipality
- Fujian Provincial Department of Science and Technology